The following information is obtained from various newswires,
published medical journal articles, and medical conference presentations.
Company: Rhone Poulenc Rorer
Approval Status: Approved February 1998
Treatment for: prevention of blood clots following hip-replacement surgery
General Information
Lovenox (enoxaparin sodium) Injection has been approved for the extended prevention of deep-vein thrombosis (DVT) following hip replacement surgery. It was previously approved for use in a hospital setting, and is the first low-molecular-weight heparin to be approved for once a day at home use.
Clinical Results
In clinical studies, patients discharged for the hospital without signs of venous thromboembolic disease received either a three-week regimen of Lovenox, or placebo. Results demonstrated that the incidence of DVT during the three-week period was significantly lower in the Lovenox patients, 7% compared to 20% for placebo.
Side Effects
Nine percent of patients reported an incidence of injection-site hematoma (bruising).
Mechanism of Action
Lovenox (enoxaparin sodium) is an antithrombotic agent known as a low-molecular-weight heparin.
